Author: Taurus

Testosterone May Slow Glioblastoma in Men and TRT Implications

Posted on by Taurus

Testosterone May Slow Glioblastoma in Men and TRT Implications

Estimated reading time: 9 minutes

Key takeaways

  • Early 2026 data from an NIH-funded Cleveland Clinic team, published in Nature, indicate that loss of testosterone accelerates glioblastoma growth in male mice by shifting brain-immune dynamics; this effect was not seen in females.
  • In human observational data, men with glioblastoma who were already receiving prescribed testosterone (for reasons unrelated to cancer) had lower mortality risk and longer median survival than matched controls. This is correlation, not proof of causation.
  • The research does not justify starting, stopping, or changing TRT to treat a brain tumor. Standard-of-care glioblastoma treatments remain unchanged.
  • For men with confirmed hypogonadism, TRT remains FDA-approved with known risks and monitoring needs (notably blood pressure and hematocrit). Any use alongside brain cancer care should be coordinated by an experienced oncology and endocrine team.
  • Open questions include whether randomized trials will confirm a survival benefit, how testosterone interacts with temozolomide, radiation, and dexamethasone, and how to optimize dosing in this context.

Table of contents

  1. What the new Cleveland Clinic study found
  2. Testosterone, brain tumors, and what the human data show—and don’t show
  3. Why this is surprising—and how the new picture fits
  4. Practical implications if you’re considering or already on TRT
  5. How could testosterone suppress glioblastoma in males?
  6. What this does not mean
  7. Questions to bring to your oncology and endocrine teams
  8. What to watch next: trials, timelines, and safety signals
  9. For Taurus Meds patients: our approach to TRT in complex cases
  10. Conclusion

Early data suggest testosterone may help restrain glioblastoma growth in men. Here’s what that could mean for TRT decisions, safety, and care coordination.

What the new Cleveland Clinic study found

In May 2026, Cleveland Clinic researchers reported that testosterone appears to suppress glioblastoma in males. In male preclinical models, depriving animals of testosterone sped up tumor growth and altered the brain’s immune environment in ways that favored the tumor. The same pattern did not hold in females, suggesting a distinctly male-specific biology at play.

The NIH highlighted the study’s importance because it challenges a long-standing narrative: that male sex hormones likely worsen aggressive cancers like glioblastoma. Men have historically had higher incidence and poorer outcomes with glioblastoma than women, which reinforced the belief that androgens were part of the problem. The new data suggest the opposite could be true for the male brain—testosterone may help restrain tumor progression by shaping immune and inflammatory pathways.

For readers following “testosterone brain tumor” research, this is a genuine pivot point: strong preclinical evidence in males, with a mechanistic rationale that lines up with observed sex differences.

Testosterone, brain tumors, and what the human data show—and don’t show

The team also examined population-level outcomes using U.S. registry data. In a SEER analysis of more than 1,300 men with glioblastoma (2008–2019), those who had been prescribed testosterone for non-cancer reasons showed a 38% lower risk of death compared with matched peers not on testosterone. Median survival was roughly 16 months in the testosterone group versus 12 months with standard chemotherapy alone.

That said, observational data cannot prove testosterone caused the improved outcomes. Men on TRT may differ in ways the registry cannot fully capture (for example, overall health status, access to specialty care, or fitness). The analysis nonetheless adds a clinically relevant signal that aligns with the male-specific preclinical biology.

The bottom line: intriguing association, not a practice-changing conclusion. Randomized controlled trials are needed to determine whether testosterone meaningfully improves survival and how it should be used alongside standard glioblastoma therapy—if at all.

Why this is surprising—and how the new picture fits

For years, clinicians generalized from other cancer settings (like prostate cancer) where androgens can fuel tumor growth. Because glioblastoma outcomes are worse in men, many assumed male hormones contributed to that gap.

The 2026 findings paint a more nuanced picture: in male brains, testosterone may calibrate immune and inflammatory responses in ways that reduce a tumor’s ability to thrive. When testosterone drops, the tumor microenvironment appears to become more permissive—more inflammatory in the wrong ways and more immunosuppressive where it matters—allowing the cancer to expand.

This sex-specific effect underscores a broader lesson in oncology and endocrinology: the same hormone can have opposite implications depending on tissue type, disease context, and sex.

Practical implications if you’re considering or already on TRT

If you are a man living with glioblastoma and also meet criteria for hypogonadism, or if you’re already receiving TRT for clinically confirmed low testosterone, here are considerations to discuss with your care team:

  • Do not start, stop, or adjust testosterone as an anti-cancer strategy without oncology guidance. Despite the promising signal, there are no randomized trials confirming a survival benefit or defining safe use with temozolomide, radiation, or dexamethasone.
  • TRT’s current role is unchanged: It is FDA-approved for men with clinical hypogonadism, typically diagnosed with symptoms plus repeatedly low morning testosterone levels. It is not approved for age-related low testosterone alone.
  • Safety updates matter. The FDA revised testosterone labeling in 2025, removing the prior boxed warning about major cardiovascular risk while adding clearer warnings about blood pressure increases. Hematocrit elevation and prostate monitoring remain standard considerations across formulations.
  • Monitoring remains essential. If you and your clinician decide that TRT is appropriate for hypogonadism, expect regular checks of blood pressure, hematocrit/hemoglobin, lipids, PSA and prostate health (as indicated), liver function (per product), and symptom response.
  • Cancer care coordination is key. Potential interactions with corticosteroids (like dexamethasone), antiepileptics, and chemotherapy agents deserve individualized review. The brain-tumor context brings unique pharmacologic and physiologic dynamics.
  • Lifestyle still matters. Sleep, nutrition, resistance training, and management of metabolic risk can support quality of life and lean mass, whether or not you use TRT. If you’re on GLP-1 therapy for weight management, discuss testosterone testing with your clinician; maintaining lean mass can be challenging during rapid weight loss.

For men searching “TRT glioblastoma” or “testosterone brain tumor,” the pragmatic message today is caution with optimism: there may be a benefit, but it has not yet been proven or integrated into guidelines.

How could testosterone suppress glioblastoma in males?

Mechanistically, the study proposes that testosterone helps maintain a brain-immune balance in males that is less favorable to glioblastoma growth. When testosterone is depleted, the tumor microenvironment shifts:

  • Inflammation becomes dysregulated, driving tumor-supportive signals rather than effective anti-tumor surveillance.
  • Immune activity within the brain tilts toward an immunosuppressive state that allows glioblastoma cells to expand.

These findings do not imply that “more is better.” Hormones exist on a spectrum where both deficiency and excess can carry risks. Any potential therapeutic window will need to be defined carefully in clinical trials, with attention to dosing, timing, and interactions with standard treatments.

What this does not mean

  • It does not mean testosterone treats brain cancer. No clinical trial has established testosterone as a therapy for glioblastoma.
  • It does not mean androgen deprivation (useful in other cancers) is advisable in brain tumors. The male-specific preclinical data suggest the opposite—but clinical confirmation is needed.
  • It does not apply to women. The key effects were observed in males; the female brain-tumor biology in this context appears different.
  • It does not endorse high-dose or unsupervised hormone use. Supraphysiologic androgens are not the same as guideline-directed TRT and may present distinct risks.

Questions to bring to your oncology and endocrine teams

  • Given my diagnosis and labs, do I meet criteria for hypogonadism that would justify TRT on its own merits?
  • If I’m already on TRT, should I continue during glioblastoma treatment? How will we coordinate monitoring?
  • Could testosterone interact with my current regimen (temozolomide, radiation, dexamethasone, antiepileptics)? What signs would prompt a change?
  • What targets will we use for testosterone levels, and how often will we measure hematocrit, blood pressure, and PSA?
  • Are there clinical trials near me evaluating testosterone or hormone modulation in glioblastoma?
  • If TRT is not appropriate, what non-hormonal strategies can support energy, mood, lean mass, and sexual health during treatment?

What to watch next: trials, timelines, and safety signals

The NIH has called attention to these findings and the need for clinical trials. Here’s what to expect as research progresses:

  • Pilot studies may first test feasibility and safety of physiologic testosterone replacement in hypogonadal men with glioblastoma, closely tracking tumor response and quality of life.
  • Larger randomized controlled trials would be needed to assess survival endpoints and define any additive benefit with standard-of-care therapy.
  • Safety analyses will focus on cardiovascular events, blood pressure changes, erythrocytosis, prostate outcomes, and neurologic status—in the specific context of brain cancer care.
  • Regulatory guidance has not changed. Until trial data mature and are reviewed, TRT should be used for established indications, not as a cancer therapy.

For Taurus Meds patients: our approach to TRT in complex cases

At Taurus Meds, we follow an evidence-informed, safety-first model:

  • We prescribe TRT only for clinically confirmed hypogonadism, not for performance enhancement or as a cancer treatment.
  • We coordinate with oncology, neurology, and primary care when patients have active or recent cancers, ensuring shared decision-making and clear monitoring plans.
  • We follow FDA guidance on blood pressure risk and hematologic monitoring across formulations, and we personalize schedules for labs and follow-up.
  • We remain engaged with emerging research and will adapt protocols as high-quality evidence develops.

If you’re a current patient with a brain tumor diagnosis—or you’re considering TRT and worried about how hormones intersect with brain health—bring these questions to your Taurus Meds clinician. We’ll review your goals, labs, and overall plan alongside your oncology team.

Conclusion

The latest evidence suggests a paradigm shift: in males, testosterone may help suppress glioblastoma growth—at least in preclinical models—and existing human data hint at a survival advantage among men already on prescribed testosterone. That’s encouraging, but it’s not a clinical directive. There are no trials yet proving that adding or maintaining TRT improves brain tumor outcomes, and there are important safety and coordination questions to resolve.

For now, the practical path is straightforward: use TRT for the right reasons (documented hypogonadism), under careful monitoring, and in full coordination with your cancer team. Stay tuned as trials clarify whether this male-specific biology can translate into better, evidence-based care.

Disclaimer

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Do not start, stop, or change any medication—including testosterone—without guidance from your licensed healthcare providers.

Sources

TRT and High-Grade Prostate Cancer What 553 Biopsies Show

Posted on by Taurus

TRT and High-Grade Prostate Cancer What 553 Biopsies Show

Estimated reading time: 8 minutes

Key takeaways

  • A prospective biopsy cohort of 553 men found the lowest positive biopsy rate in hypogonadal patients on TRT (16.7%) versus untreated hypogonadal men (51.9%) and eugonadal men (37.8%).
  • Cancers identified in the TRT group skewed lower grade (71.4% Gleason ≤6), with fewer high-grade findings than other groups.
  • Findings align with the androgen receptor “saturation hypothesis,” suggesting limited additional prostatic stimulation once a low testosterone threshold is met.
  • Evidence is preliminary due to a small TRT cohort (n=42) and potential selection effects; larger, longer trials are needed.
  • For appropriately selected hypogonadal men under monitoring, current data do not show elevated biopsy-proven prostate cancer risk with TRT.

Table of contents

  1. Overview
  2. Why biopsy-based data matters
  3. Inside the 553-patient study: design and findings
  4. The saturation hypothesis: a plausible biological explanation
  5. What this does—and does not—prove
  6. What do other studies say?
  7. Practical implications if you’re considering TRT
  8. Safety beyond the prostate: what else to weigh
  9. How Taurus Meds approaches TRT and prostate risk
  10. Open questions and what to watch
  11. Bottom line

Overview

Interest in testosterone replacement therapy (TRT) has grown alongside lingering concerns about prostate cancer. Historically, some feared that restoring testosterone might “fuel” occult tumors. A prospective biopsy study of 553 men offers a counterpoint: hypogonadal men on TRT had the lowest rate of positive biopsies and the lowest-grade cancers compared with both untreated hypogonadal and eugonadal men. While these findings are not definitive, they contribute to evidence suggesting TRT does not increase prostate cancer risk and may be associated with fewer high-grade diagnoses under appropriate monitoring.

Why biopsy-based data matters

Much of the caution around testosterone and the prostate comes from older assumptions and case reports rather than large, modern biopsy-confirmed datasets. PSA can fluctuate with age, prostate size, infection, and treatment-related changes, making it an imperfect signal on its own. Biopsy-confirmed outcomes matter because they provide a direct, pathological readout of cancer presence and grade.

The 2017 prospective biopsy study highlighted here collected outcomes in men who actually underwent prostate biopsy, enabling clearer comparisons among eugonadal men, untreated hypogonadal men, and hypogonadal men on TRT. For patients and clinicians, biopsy-based data help answer a practical question: what is the true, biopsy-proven risk signal in the context of TRT?

Inside the 553-patient study: design and findings

A 2017 prospective analysis examined 553 men who underwent prostate biopsy between 2008 and 2013, comparing three groups:

  • Hypogonadal men on TRT (n=42)
  • Hypogonadal men not on TRT (n=27)
  • Eugonadal men (n=484)

Key results:

  • Positive biopsy rates: 16.7% (TRT) vs 51.9% (untreated hypogonadal) vs 37.8% (eugonadal).
  • Cancer severity: Among men in the TRT group who had cancer, 71.4% had Gleason ≤6 (lower grade), with the overall severity distribution lowest in the TRT cohort.

Thus, cancers were detected less often in men on TRT, and when present, tended to be lower grade—contradicting the notion that restoring testosterone inevitably accelerates disease.

Limitations matter. The TRT group was small (n=42), and although biopsies were prospectively captured, selection effects and confounders (referral patterns, thresholds for biopsy, and characteristics of men who choose TRT) cannot be excluded. Still, these data offer a compelling, biopsy-based contribution to a safety discussion that often leans on outdated assumptions.

The saturation hypothesis: a plausible biological explanation

The leading explanatory model is the saturation hypothesis. Prostate tissue requires androgens to grow, but androgen receptors become saturated at relatively low testosterone concentrations. Above that threshold, additional testosterone has minimal extra stimulatory effect.

This helps explain why restoring testosterone from low to normal may not linearly increase cancer risk and why observations can show stable or improved prostate parameters under monitored TRT. The 2017 biopsy findings are consistent with this model: once men are at or beyond the “saturation point,” further prostatic stimulation may be negligible, while other factors may underlie higher positivity rates among untreated hypogonadal men.

What this does—and does not—prove

  • Suggests reassurance, not causation: TRT was not associated with higher biopsy-proven cancer rates or grades; if anything, a favorable signal appeared for high-grade disease.
  • Small TRT cohort: Precision and generalizability are limited (n=42).
  • Potential selection bias: Health behaviors, medical oversight, and detection pathways may differ for men who initiate TRT.
  • Follow-up horizon: Biopsy is a strong point-in-time measure, but long-term risk (10+ years) needs larger, longitudinal datasets and randomized trials.

Bottom line: the data are encouraging but not definitive. The most defensible current interpretation is that TRT does not appear to raise biopsy-proven prostate cancer risk in hypogonadal men under routine screening.

What do other studies say?

Additional analyses support context:

  • A 2017 cohort of 224 men found no increase in prostate cancer detection among those receiving TRT versus non-TRT peers (25% vs 32.1%; p=0.757).
  • Retrospective series of men post–prostate cancer treatment (surgery or radiation) generally report no worse oncologic outcomes with carefully selected, closely monitored TRT.

Collectively, these observational data suggest that, for appropriately evaluated candidates, TRT does not drive higher biopsy-proven cancer risk—though none of the studies were designed to test whether TRT prevents high-grade cancer.

Practical implications if you’re considering TRT

  • Expect evaluation: Repeat morning testosterone tests, PSA screening, and a prostate exam are common before starting therapy to rule out active prostate cancer.
  • Monitoring continues: Many clinicians track PSA and clinical status at regular intervals, especially in the first year.
  • Context matters: Age, family history, prior pathology, baseline PSA, symptoms, and personal preferences all guide decisions.
  • Not for everyone: TRT is generally inappropriate for eugonadal men or for those with known or suspected prostate cancer.

For patients, the key takeaway is that modern biopsy-based data do not show an increased prostate cancer risk signal with TRT in hypogonadal men under appropriate surveillance—supporting an informed, individualized choice.

Safety beyond the prostate: what else to weigh

  • Erythrocytosis: Increased red cell mass may require dose adjustments or other interventions; hematocrit monitoring is common.
  • Blood pressure: Recent FDA reviews and approvals of oral testosterone undecanoate emphasize BP monitoring due to observed ambulatory BP elevations in some patients.
  • Cardiovascular outcomes: The evidence base is mixed; current labeling emphasizes monitoring and individualized risk assessment.
  • Formulation differences: Topical, injectable, and oral options vary in pharmacokinetics and side-effect profiles; selection should match goals, history, and logistics.

How Taurus Meds approaches TRT and prostate risk

  • Evidence-guided discussions, including biopsy-based findings, to clarify what is known and unknown for each patient.
  • Appropriate baseline assessment and regular follow-up aligned with clinical standards and product labeling (prostate and cardiovascular parameters included).
  • Formulation and dosing tailored to goals and safety profile, with plan adjustments as needs or evidence evolve.

Our objective is clarity and safety—helping men make informed choices without hype.

Open questions and what to watch

  • Long-term protection: Does TRT reduce high-grade prostate cancer incidence over 10–15 years?
  • Subgroups: Are findings consistent across age, baseline PSA, family history, and different formulations?
  • Post-cancer scenarios: For men after definitive prostate cancer treatment, what are optimal timelines, thresholds, and monitoring strategies for considering TRT?

Future prospective registries and randomized studies with standardized biopsy criteria, PSA kinetics, imaging, and long-term follow-up are needed for definitive answers.

Bottom line

For hypogonadal men weighing therapy, the 553-patient prospective biopsy study is reassuring: men on TRT had the lowest rate of positive biopsies and, when cancer was present, it tended to be lower grade. While this is not proof of a protective effect, the findings align with the saturation hypothesis and other observational analyses showing no increased biopsy-proven prostate cancer risk in appropriately selected patients under active monitoring.

Decision-making should remain individualized, balancing symptoms, lab-confirmed testosterone levels, personal and family history, and comfort with ongoing monitoring.

Disclaimer

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about testing or therapy should be made with a qualified healthcare professional who can consider your individual circumstances.

Sources

FDA opens path for TRT for low libido in idiopathic hypogonadism

Posted on by Taurus

FDA opens path for TRT for low libido in idiopathic hypogonadism

Estimated reading time: 9 minutes

Key takeaways

  • The FDA is encouraging sNDAs to add a new TRT indication: treatment of low libido in men with idiopathic hypogonadism; this is not a blanket approval.
  • Signal follows a Dec 2025 expert panel review of RCTs suggesting benefit for libido in appropriately selected men with low testosterone.
  • The move does not apply to age-related testosterone decline; the focus is idiopathic hypogonadism only.
  • Safety emphasis: class warning for blood pressure increases and elevated risks of AF, AKI, and PE despite non-inferiority for MACE.
  • Practical impact awaits product-specific sNDA approvals, potentially extending into 2027.

Table of contents

  1. Introduction
  2. What changed in 2026—and why it matters
  3. Idiopathic hypogonadism vs. age-related low T
  4. What evidence the FDA considered
  5. Safety picture in 2026
  6. What this means for men considering TRT
  7. Considerations for clinicians
  8. Open questions the field is watching
  9. Where Taurus Meds fits
  10. Conclusion
  11. Disclaimer
  12. Sources

Introduction

A quiet but important regulatory shift arrived this spring: the FDA signaled openness to a new indication for testosterone replacement therapy (TRT)—treating low libido in men with idiopathic hypogonadism (unexplained low testosterone). The agency has invited manufacturers to submit supplemental applications (sNDAs) to support this specific use. While not an approval, it marks a meaningful departure from the prior, narrower framework that largely limited TRT labeling to men with known genetic or structural causes of hypogonadism.

This article unpacks what changed, why it matters, what the evidence says, and how to think about the benefits and risks if you’re exploring TRT for idiopathic hypogonadism in 2026.

What changed in 2026—and why it matters

For years, FDA-approved TRT labeling focused on men with clearly defined hypogonadism due to identifiable structural or genetic causes (e.g., pituitary or testicular disease, congenital syndromes). Men with low T of unclear etiology—commonly termed idiopathic hypogonadism—were generally outside labeled indications, especially if low T appeared age-related.

In April 2026, the FDA announced it is open to a new TRT indication focused narrowly on a symptom—low libido—in men with idiopathic hypogonadism. The agency invited manufacturers to contact FDA and submit sNDAs by April 30, 2026. The shift follows a December 2025 expert panel discussion of RCT evidence and reflects the agency’s view that carefully selected men with unexplained low testosterone may experience clinically meaningful improvements in libido with TRT.

Important caveats:

  • No approvals have been granted yet. Each product will need to demonstrate substantial evidence of effectiveness and a favorable risk-benefit profile for the proposed population.
  • The pathway is symptom-specific (low libido) and population-specific (idiopathic hypogonadism). It does not extend TRT to age-related low T or other conditions.

For men and clinicians, this could eventually mean clearer on-label access to TRT for low libido when low testosterone is present but no structural or genetic cause is found—provided safety and efficacy standards are met in sNDAs.

Idiopathic hypogonadism vs. age-related low T: the crucial distinction

Understanding the boundary between idiopathic hypogonadism and age-related decline is central to the FDA’s 2026 posture.

  • Idiopathic hypogonadism: Persistently low testosterone without an identifiable genetic or structural cause after appropriate evaluation. Symptoms can include low libido, fatigue, depressed mood, and reduced muscle mass. Biochemical thresholds vary by guideline (often total testosterone below ~280–350 ng/dL on morning testing), and confirmation typically requires repeat measures and clinical correlation.
  • Age-related hypogonadism: Lower testosterone levels commonly observed with aging, often multifactorial (health status, medications, adiposity, sleep). The current FDA signaling does not extend to late-onset, age-associated low T.

In practice, distinguishing these categories can be clinically challenging. Symptoms overlap, thresholds vary, and comorbidities complicate interpretation. The FDA’s sNDA pathway underscores the need for rigorous diagnostic criteria in submissions to ensure the right patients are targeted.

What evidence the FDA considered

The agency’s update references “rigorous, well-controlled RCT literature,” with a December 2025 expert panel review central to its shift. While specific trials cited by the panel were not fully detailed publicly, several lines of evidence inform the conversation:

  • Libido and sexual function: Multiple RCTs and systematic reviews report improvements in libido and erectile function among hypogonadal men treated with TRT, forming one of the most consistent benefit signals in the literature (Corona et al., 2020). This aligns with the agency’s symptom-focused lens on low libido.
  • Oral testosterone undecanoate (oTU): A recent meta-analysis showed oTU significantly increases testosterone in hypogonadal men versus placebo and is generally well tolerated without significant increases in adverse events compared with placebo. Notably, in eugonadal participants, oTU paradoxically decreased testosterone, reinforcing the importance of correct patient selection and avoiding therapy in men with normal baseline T (Sex Med Rev, 2023).
  • Body composition and metabolic markers: In men in their 40s with biochemically confirmed hypogonadism, studies report gains in lean mass, reductions in fat mass, improved insulin sensitivity, and smaller waist circumference—especially when paired with lifestyle interventions (Cureus, 2025). While encouraging, these are supportive outcomes; the FDA’s near-term pathway is explicitly tied to low libido improvement.
  • Limited age-related data: RCT evidence in age-related hypogonadism remains limited, with more heterogeneity and fewer trials (PubMed review, 2020). This evidence gap supports the FDA’s decision to focus on idiopathic cases rather than expand broadly to late-onset low T.

Bottom line: The clearest efficacy signal for TRT across hypogonadal populations has been sexual desire/libido and erectile function. The 2026 FDA update narrows in on that signal for a carefully defined group—men with idiopathic hypogonadism.

Safety picture in 2026: what stays the same—and what’s evolving

TRT’s safety profile remains a key part of any potential label expansion.

  • Blood pressure increases: In February 2025, the FDA updated TRT labeling with a class-wide warning about clinically meaningful increases in blood pressure observed across formulations, based on ambulatory BP monitoring data. A prior boxed warning for major cardiovascular events (MACE) was removed but replaced with this BP-specific warning.
  • Atrial fibrillation (AF), acute kidney injury (AKI), pulmonary embolism (PE): A large, contemporary randomized safety trial (TRAVERSE; 2026, in press) found non-inferiority for MACE but higher rates of AF, AKI, and PE in the testosterone group relative to placebo. Some data suggest an early risk window for venous thromboembolism in the first 3–6 months after starting therapy.
  • Erythrocytosis: Elevations in hematocrit are well-documented, especially with long-acting injectable formulations, and often necessitate dose adjustments or other management.
  • Prostate and fertility: Ongoing attention to prostate health is standard in men on TRT. Additionally, exogenous testosterone can suppress spermatogenesis, which is consequential for men considering future fertility.

The FDA’s eventual labeling for any new indication will likely continue to emphasize blood pressure monitoring, cardiovascular risk assessment, and careful surveillance for hematologic and thromboembolic events. These considerations apply across formulations (gels, injections, oral TU), with nuances that may be addressed on a product-specific basis in sNDAs.

What this means for men considering TRT for low libido

  • Potential benefits: Men who meet biochemical and clinical criteria may experience meaningful improvements in libido. Secondary gains in energy, mood, or body composition are reported in some studies but are not the focus of the FDA’s current pathway.
  • Patient selection remains crucial: The paradoxical decrease in testosterone observed with oral TU in eugonadal men underscores that TRT is not benign or universally appropriate. Precise diagnosis and ongoing monitoring matter.
  • Monitoring likely unchanged: Blood pressure checks, hematocrit surveillance, prostate health assessment, and cardiovascular risk review will remain part of responsible care. Early vigilance for AF, AKI, and thromboembolic events is warranted given emerging safety signals.
  • Timelines: Even if manufacturers meet the April 30, 2026 engagement window, FDA review of supplemental applications typically spans 6–12 months. Approvals, if granted, could extend into 2027.
  • Insurance and access: On-label indications often facilitate coverage, but payer policies vary. Final labeling, required monitoring, and product choice (gel, injection, oral) could influence access and out-of-pocket costs.

Considerations for clinicians

  • Current practice is unchanged until sNDAs are approved. Off-label prescribing remains subject to clinical judgment, but promotion beyond existing labels is restricted.
  • The FDA’s narrow focus on low libido in idiopathic hypogonadism is deliberate. Broader claims around depression, cardiovascular disease, or diabetes—raised by some experts—are not part of this pathway.
  • Documentation may matter more: Clear diagnostic workups distinguishing idiopathic hypogonadism from age-related decline will likely align with future labeling and payer expectations.
  • Shared decision-making: Communicate evolving evidence, the specific symptom target (libido), and safety trade-offs, particularly related to blood pressure and thromboembolic risk.

Open questions the field is watching

  • Which specific RCTs underpinned the December 2025 expert panel’s conclusions, and how strong are the data on libido endpoints?
  • What primary efficacy endpoints will FDA require for sNDA approval—validated sexual function scales, patient-reported outcomes, or biochemical targets?
  • How will regulatory submissions define idiopathic hypogonadism versus age-related decline in a way that is both clinically practical and scientifically rigorous?
  • Will approvals, if granted, include enhanced monitoring programs or restricted distribution pathways in light of AF, AKI, and PE signals?
  • What will the total review time be for sNDAs initiated after April 30, 2026, and when might first approvals realistically land?
  • How will labels incorporate the TRAVERSE trial’s non-MACE safety signals and the 2025 BP warning across formulations?

Where Taurus Meds fits

Taurus Meds follows these regulatory updates closely so patients and clinicians can make informed choices as the landscape evolves. If sNDAs are approved, we’ll help:

  • Track which products receive the new indication and how labeling differs by formulation.
  • Clarify monitoring expectations such as blood pressure and hematologic checks, and coordinate logistics where appropriate.
  • Share practical updates on coverage and access as payers react to any label changes.

Our goal is to keep you current on evidence and policy—so decisions about TRT for idiopathic hypogonadism remain grounded, cautious, and patient-centered.

Conclusion

The FDA’s 2026 signal is a measured step: a focused path to on-label TRT use for low libido in men with idiopathic hypogonadism, pending product-specific evidence. It does not expand TRT to age-related low T, nor does it endorse broader disease-modifying claims. The evidence for libido improvement is among the most consistent findings in hypogonadal men, but safety considerations—especially blood pressure, thromboembolic risk, AF, and AKI—remain paramount.

If you’re exploring TRT for low libido with documented low testosterone and no clear structural cause, this development may eventually widen on-label options. For now, the prudent approach is to stay informed, weigh potential benefits against known risks, and continue shared decision-making with a qualified clinician as the regulatory story unfolds.

Disclaimer

This article is for informational purposes only and is not medical advice. Decisions about testing or treatment should be made with a qualified healthcare professional who can consider your individual circumstances.

Sources

Oral TRT Tlando Jatenzo Kyzatrex Efficacy and Blood Pressure

Posted on by Taurus

Oral TRT Tlando Jatenzo Kyzatrex Efficacy and Blood Pressure

See how Tlando, Jatenzo, and Kyzatrex stack up on restoring testosterone, dosing, and side effects. Learn why routine blood pressure checks matter with oral TRT.

Estimated reading time: 10 minutes

Key takeaways

  • Oral testosterone undecanoate (TU) capsules—Tlando, Jatenzo, Kyzatrex—restored average testosterone to the eugonadal range for most men in Phase 3 trials.
  • Small but consistent systolic blood pressure increases (about 1.7–5 mmHg by ABPM) occur across studies; effects may be larger in men on antihypertensives—monitor BP routinely.
  • No hepatotoxicity signals with modern oral TU compared with older 17-alpha-alkylated androgens.
  • Dosing differs: Kyzatrex and Jatenzo are titrated; Tlando is fixed-dose (225 mg twice daily). Food effects and adherence matter.
  • FDA labeling (post-TRAVERSE) removes the prior boxed warning for MACE and emphasizes a class-wide warning about BP increases.

Table of contents

  1. Overview
  2. What Is Oral Testosterone Undecanoate and Why It’s Different
  3. What the Phase 3 Trials Show
  4. Blood Pressure: Small Increases That Matter Clinically
  5. Titration and Monitoring: What Patients Can Expect
  6. Oral TU vs Injectables: Pharmacokinetics and Patient Experience
  7. Who Might Consider Oral TRT—and Who Should Be Cautious
  8. Limitations and What We Still Don’t Know
  9. How Taurus Meds Approaches Oral TRT Choices
  10. Conclusion

Overview

Men weighing testosterone therapy increasingly ask about oral options that avoid needles yet reliably restore testosterone. Oral testosterone replacement therapy (TRT) with testosterone undecanoate (TU) capsules—Tlando, Jatenzo, and Kyzatrex—now offers a credible alternative to injections for many hypogonadal men. Phase 3 pharmacokinetic (PK) trials show these formulations can achieve eugonadal testosterone levels with structured dosing and titration, without the liver toxicity associated with older oral androgens. The key nuance: small but measurable increases in blood pressure (BP) have been observed and are now emphasized across product labeling, making BP monitoring an essential part of care.

This article compares what the major oral TU options deliver, what their trial data actually show, and what practical monitoring looks like for real patients.

What Is Oral Testosterone Undecanoate and Why It’s Different

Testosterone undecanoate is a long-chain fatty acid ester of testosterone. Oral TU capsules are absorbed via the intestinal lymphatic system, which helps bypass first-pass hepatic metabolism. That pharmacology is essential to two points men frequently ask about:

  • Liver safety: Unlike older oral androgens (for example, 17-alpha-alkylated compounds), modern oral TU formulations in Phase 3 programs have not shown liver toxicity signals.
  • Food and absorption: Historically, oral TU has required administration with meals—especially dietary fat—to optimize absorption. While labels differ, men should expect clinicians to discuss meal timing and consistency. Some recent data suggest Kyzatrex may be less dependent on meal fat than older formulations, but patients should follow product-specific guidance.

In routine care, the “oral vs injectable” conversation often comes down to preference (needle-averse, travel, convenience), adherence (twice-daily dosing), and physiology (avoiding supraphysiologic peaks and deep troughs more typical of some injectable regimens).

What the Phase 3 Trials Show

Across the three FDA-approved oral TU capsules, pivotal and supportive studies consistently demonstrate restoration of total testosterone (TT) to target ranges for the majority of treated men. Each product follows its own dosing and titration framework.

  • Kyzatrex (MRS-TU-2019EXT; FDA 2022)
    • Population: Hypogonadal men; median age around 50; most were overweight or obese—important when thinking about generalizability.
    • Efficacy: Approximately 87.8% (worst-case) to 96.1% (completers) achieved eugonadal average TT by Day 90. Mean Cavg was about 452 ng/dL, and free T approximately doubled from baseline (roughly 7.0 to 14.1 ng/dL).
    • Dosing: Titrated within 100–400 mg twice daily based on on-therapy testosterone levels.
    • Notes: FDA review documents discuss site-specific data integrity concerns that were addressed in the final efficacy analysis; the Phase 3 extension met prespecified endpoints after excluding a problematic site per protocol.
  • Jatenzo (CLAR-15102; FDA 2019)
    • Population: Hypogonadal men studied in a PK-driven Phase 3 program.
    • Efficacy: Met FDA PK criteria for achieving average testosterone in the eugonadal range.
    • Dosing: Typically starts at 237 mg twice daily with subsequent titration based on follow-up labs.
  • Tlando (Full FDA approval 2023)
    • Population: Hypogonadal men; program focused on fixed-dose feasibility.
    • Efficacy: A fixed 225 mg twice-daily dose restored eugonadal testosterone without titration.
    • Dosing: Not titrated, which can simplify use for men and clinicians who prefer a fixed approach.

Despite differences in titration philosophy, the overarching story is similar: oral TU reliably normalizes average testosterone in most treated men when dosing is selected and adjusted according to product labeling and measured TT. It is common for clinicians to aim for a mid-normal average TT with symptom improvement while minimizing side effects.

Blood Pressure: Small Increases That Matter Clinically

BP effects are the most consistent class signal across oral TU trials and FDA reviews. Measurements by ambulatory blood pressure monitoring (ABPM) avoid clinic “white coat” effects and give a clearer picture of on-therapy changes:

  • Kyzatrex: ABPM showed an average systolic increase of about +1.7 mmHg (95% CI 0.3–3.1) and diastolic +0.6 mmHg at steady state, with a plateau over time. In men already on antihypertensives, the systolic increase was larger (about +3.4 mmHg).
  • Jatenzo and Tlando: FDA reviewers report average systolic increases roughly in the 3–5 mmHg range on ABPM, depending on the study cohort and time point.

How should patients interpret this? On an individual level, a few mmHg may or may not move a person across a diagnostic threshold—but from a population-health perspective, even small BP rises can matter. Given how common hypertension, diabetes, and obesity are among men seeking TRT, the pragmatic response is not alarm, but routine measurement:

  • Establish baseline BP prior to starting oral TRT.
  • Check BP periodically on therapy; clinicians increasingly use home BP measurements and ABPM in higher-risk patients.
  • Be aware that injectable and transdermal TRT can also affect BP. For context, the weekly subcutaneous testosterone enanthate autoinjector has shown a systolic rise of ~4 mmHg in some studies, so BP considerations are not unique to oral TU.

As of early 2025, FDA labeling reflects outcomes from the large TRAVERSE trial by removing the prior class boxed warning for MACE while adding or highlighting a class-wide warning about BP increases. The net message for patients: TRT does not appear to raise major cardiovascular events overall compared with placebo in appropriately selected men, but modest BP elevations are sufficiently consistent to warrant proactive monitoring.

Titration and Monitoring: What Patients Can Expect

Individualized dosing and regular follow-up are central to safe, effective TRT—oral or otherwise. While exact steps are determined by a prescribing clinician, the Phase 3 programs and FDA labels suggest several practical themes:

  • Confirm the diagnosis carefully:
    • Most clinicians confirm low testosterone on two separate morning samples, alongside consistent symptoms, before initiating TRT.
  • Choose an oral TU strategy aligned with monitoring preferences:
    • Kyzatrex: Titration within 100–400 mg twice daily, with dose adjustments to keep average TT eugonadal.
    • Jatenzo: Typically starts at 237 mg twice daily, then titrates up or down based on follow-up TT.
    • Tlando: Fixed 225 mg twice daily—no titration—which may simplify follow-up for some men.
  • Consider food effects:
    • Many oral TU capsules are taken with food to support absorption. Some data suggest Kyzatrex is less dependent on meal fat than earlier capsules; patients should follow the specific product label and clinician advice.
  • Monitor at regular intervals (often every 3–6 months once stable):
    • Testosterone and, when appropriate, free T to verify eugonadal levels.
    • Hematocrit/hemoglobin to watch for erythrocytosis.
    • BP at baseline and on therapy; home BP logs or ABPM can be useful, especially if cardiovascular risk is present.
    • Prostate health monitoring consistent with age and risk (e.g., PSA where indicated).
  • Manage comorbidities in parallel:
    • In the oral TU trials, a sizable proportion of men had hypertension, diabetes, or dyslipidemia at baseline; a small fraction started new antihypertensives during the studies. Coordinated primary care and cardiometabolic risk management remain important.

These points are not prescriptive directions; they illustrate the kind of structured, lab-informed care many clinics employ with oral TRT.

Oral TU vs Injectables: Pharmacokinetics and Patient Experience

  • Peaks and troughs: Twice-daily oral TU targets steady-state testosterone within the eugonadal window, aiming to minimize the high peaks and low troughs common with some injection schedules. This can matter for symptom stability and side-effect profiles.
  • Adherence trade-offs: Oral capsules avoid needles and in-office injections but rely on consistent twice-daily adherence, often with meals, to maintain stable exposure.
  • Side effects and risks: Erythrocytosis, acne/oily skin, edema, and reduced fertility potential are class effects to consider, regardless of route. Oral TU has not shown the hepatotoxicity associated with 17-alpha-alkylated androgens.
  • Blood pressure: Small BP rises are seen with several TRT modalities. With oral TU, the effect is measurable by ABPM, and labels now call for attention to BP across the class.

For many men who are needle-averse or who prefer a convenient, home-based option, oral testosterone replacement therapy can be an attractive path—particularly when combined with thoughtful monitoring and periodic dose re-assessment.

Who Might Consider Oral TRT—and Who Should Be Cautious

Oral TU may be a good fit for:

  • Men with confirmed hypogonadism who prefer to avoid injections
  • Those seeking a PK profile designed to avoid supraphysiologic peaks
  • Patients comfortable with twice-daily dosing and routine lab/clinic follow-ups

Caution or avoidance is generally prudent in:

  • Prostate or male breast cancer
  • Severe, symptomatic benign prostatic hyperplasia
  • Uncontrolled hypertension or significant, unstable cardiovascular disease
  • Men actively trying to conceive (TRT commonly suppresses gonadotropins and reduces fertility potential)
  • Individuals with markedly elevated baseline hematocrit

A balanced consultation typically weighs symptoms, lab values, comorbidities, preferences, and logistics—and includes a plan for follow-up BP checks, labs, and dose adjustments.

Limitations and What We Still Don’t Know

  • Trial design and duration: Many oral TU trials are single-arm or open-label with modest sample sizes and short follow-up (often up to six months). That limits conclusions on long-term outcomes.
  • Population generalizability: Participants were predominantly overweight or obese. How best to titrate in lean, very obese, or older populations remains an active question.
  • Comparative data: Head-to-head trials among oral TU options—or direct comparisons versus popular injectable schedules—are limited.
  • Long-term outcomes: While TRAVERSE supports cardiovascular safety at the class level for appropriately selected patients, ongoing questions remain around longer-term effects on prostate endpoints, fertility, atrial arrhythmias, and kidney outcomes flagged in some analyses.
  • Metabolic therapies: As GLP-1 receptor agonists and other weight-loss drugs become more common, we need more data on how they interact with TRT regarding lean mass, dose needs, and cardiometabolic risk.

How Taurus Meds Approaches Oral TRT Choices

For men considering oral testosterone replacement therapy, Taurus Meds emphasizes:

  • Careful confirmation of hypogonadism and shared decision-making about route
  • Realistic expectations about benefits and uncertainties
  • Structured monitoring that includes BP, hematology, and testosterone targets
  • Collaboration with primary care and cardiology when cardiovascular risk is present

That approach helps men choose between Tlando, Jatenzo, Kyzatrex, injectables, or transdermal options based on clinical context and personal priorities—without overpromising outcomes.

Conclusion

Modern oral TU capsules—Tlando, Jatenzo, and Kyzatrex—represent a meaningful expansion in TRT choices. Across Phase 3 programs, they reliably bring average testosterone into the eugonadal range for most hypogonadal men, with no liver toxicity signals and a PK profile designed to avoid large peaks and troughs. The main trade-off to keep in view is small but consistent blood pressure increases detectable on ABPM. For many, that is manageable with baseline assessment and on-therapy monitoring—particularly relative to the practical advantages of an oral regimen.

If you are exploring TRT, an informed conversation with a clinician about diagnosis confirmation, goals, titration options, BP monitoring, and fertility considerations is the best next step. Oral TRT is not magic—but for the right patient, it can be a well-matched and evidence-supported solution.

Disclaimer

This content is for educational purposes only and is not medical advice. Do not start, change, or stop any medication based on this article. Consult a qualified clinician about your specific situation.

Sources

FDA opens path to TRT for low libido in idiopathic hypogonadism

Posted on by Taurus

FDA opens path to TRT for low libido in idiopathic hypogonadism

The FDA is open to reviewing TRT for low libido in men with idiopathic hypogonadism, but no products are approved yet. See potential eligibility and key safety considerations.

Estimated reading time: 8 minutes

Key takeaways

  • The FDA invited supplemental applications to evaluate TRT for treating low libido in men with idiopathic hypogonadism—no approvals yet.
  • This does not extend to age-related testosterone decline; existing indications remain unchanged.
  • Safety signals (blood pressure increases, erythrocytosis, atrial fibrillation, AKI, pulmonary embolism) keep monitoring central to care.
  • Potential future labels would likely require strict diagnostic criteria, symptom documentation, and ongoing follow-up.
  • Manufacturers have been asked to align with the FDA on evidence requirements in 2026 before any label changes.

Table of contents

  1. What exactly did the FDA announce?
  2. Idiopathic hypogonadism vs. age-related low testosterone
  3. Why now? The evidence the FDA considered
  4. What hasn’t changed
  5. If approved, who might qualify?
  6. Practical implications for patients now
  7. Safety, monitoring, and known risks
  8. What sponsors must prove next
  9. Why this matters for the TRT community
  10. How Taurus Meds can support patients
  11. The bottom line

What exactly did the FDA announce?

On April 16, 2026, the FDA said it is open to reviewing supplemental NDAs for a new TRT indication: treatment of low libido in men with idiopathic hypogonadism. The agency’s statement follows review of published trials and discussions at a December 2025 expert panel. Importantly:

  • No TRT product has been approved for this new indication yet.
  • The FDA is asking companies to meet with the agency and present robust safety and efficacy data tailored to this patient group.
  • Existing approvals—primarily for hypogonadism due to structural or genetic causes—remain unchanged.

In effect, the FDA is signaling that evidence to date may justify a narrow, symptom-targeted expansion (low libido) in a specific diagnosis (idiopathic hypogonadism), if manufacturers can meet the statutory bar for substantial evidence.

Idiopathic hypogonadism vs. age-related low testosterone

Clear definitions matter for patients, clinicians, and insurers. The FDA’s position focuses on idiopathic hypogonadism—not age-related testosterone decline.

  • Idiopathic hypogonadism: Low testosterone with symptoms and no identifiable cause after appropriate evaluation. Men may have persistent low total testosterone (often defined as <300 ng/dL on repeat morning testing) and symptoms like low sexual desire, yet lack structural pituitary/testicular disease or reversible causes (medications, obesity-related suppression, acute illness). The “idiopathic” label implies careful exclusion of known drivers.
  • Structural or genetic hypogonadism: Longstanding approved indication. Examples include congenital forms (e.g., Klinefelter syndrome) or acquired damage to the testes or pituitary.
  • Age-related testosterone decline: Common with aging and multiple comorbidities but remains outside current FDA-supported indications for TRT.

The FDA’s new openness is deliberately narrow. It centers on a functional symptom—low libido—within idiopathic hypogonadism, where some trials suggest TRT can normalize testosterone and improve sexual desire.

Why now? The evidence the FDA considered

  • Restoring testosterone levels: Across FDA-approved products for established hypogonadism (e.g., Xyosted, Kyzatrex, Tlando), consistent pharmacokinetics and safety profiles show that TRT can reliably bring average serum testosterone back into a eugonadal range (roughly 300–1000 ng/dL), aligning with prior regulatory standards on exposure and consistency.
  • TRAVERSE trial safety: In hypogonadal men at elevated cardiovascular risk, TRT was non-inferior to placebo for major adverse cardiovascular events (MACE) with a hazard ratio of 0.96 (95% CI 0.78–1.17). While reassuring for MACE, the trial reported higher rates of certain adverse events in the TRT arm, including atrial fibrillation, acute kidney injury, and pulmonary embolism—warranting continued vigilance.
  • Postmarket safety updates: The FDA emphasizes class-wide risks, including increases in blood pressure (class warning updated in 2025), erythrocytosis, potential effects on the prostate, possible worsening of sleep apnea, and observational links to early venous thromboembolism risk.

Together, this body of evidence appears sufficient, in the FDA’s view, to justify evaluating sNDAs for low libido in idiopathic hypogonadism—but it does not replace the rigorous, product-specific data required before granting any label change.

What hasn’t changed

  • No immediate access change: Clinicians cannot prescribe TRT “on-label” for low libido in idiopathic hypogonadism until specific products are approved.
  • Age-related low T remains excluded: The FDA is not endorsing TRT for typical, age-related testosterone decline or general well-being.
  • Risk profile remains central: Monitoring for blood pressure, hematocrit, and prostate health remains standard for any TRT use.

If approved, who might qualify?

If sponsors submit convincing sNDAs and the FDA grants approvals, candidates would likely be:

  • Men with clearly documented low testosterone on repeat morning testing (commonly <300 ng/dL) plus persistent low sexual desire.
  • Those with appropriate evaluation excluding structural, genetic, or reversible causes (e.g., hyperprolactinemia, pituitary disease, testicular injury, medication effects, significant systemic illness).
  • Individuals assessed for cardiovascular risk, sleep apnea, polycythemia risk, and prostate health before and during therapy.

Even with a new label, access will likely depend on careful diagnosis and monitoring to ensure benefits outweigh risks.

Practical implications for patients now

  • If you are exploring TRT for low libido: Certain products could eventually carry a label for low libido in idiopathic hypogonadism. For now, seek a thorough evaluation and discuss all options.
  • If you’re already on TRT: Your labeled indication does not change. Continue routine monitoring (blood pressure, hematocrit/hemoglobin, PSA as appropriate) and report new symptoms such as leg swelling, chest pain, shortness of breath, irregular heartbeat, or worsening sleep apnea.
  • If you have low testosterone but no clear cause: A precise workup is essential. Future labels will likely hinge on documentation of persistent low testosterone, relevant symptoms, and exclusion of known causes.
  • Insurance and coverage: A new indication could improve coverage pathways for this subset of men, though payer policies vary and may lag regulatory updates.

Safety, monitoring, and known risks

TRT’s benefits must be balanced with well-characterized risks. The FDA highlights:

  • Blood pressure increases: Monitor and manage blood pressure, especially in men with hypertension or cardiovascular risk.
  • Erythrocytosis: Periodic labs are standard; dose adjustments or pauses may be needed if hematocrit rises too high.
  • Cardiovascular signals beyond MACE: Higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism were noted in some analyses; weigh individual risk factors.
  • Prostate considerations: Monitor lower urinary tract symptoms and consider PSA testing as clinically indicated.
  • Sleep apnea: Symptoms can worsen; evaluate and treat as appropriate.
  • Fertility: Exogenous testosterone can suppress spermatogenesis; discuss alternatives if pursuing fertility.

What sponsors must prove next

  • Clear diagnostic criteria: Confirm patients truly had idiopathic hypogonadism, not age-related decline or reversible causes.
  • Clinically meaningful endpoints: Validated measures of sexual desire/libido demonstrating consistent improvement over placebo.
  • Longitudinal safety: Adequate data on cardiovascular, thrombotic, renal, hematologic, and prostate-related risks, including early risk windows.
  • Generalizability and subgroups: Clarity across age bands, baseline cardiovascular risk, and comorbidities.

The FDA has asked companies to align on data needs by April 30, 2026—signaling high regulatory rigor.

Why this matters for the TRT community

For years, patients and clinicians have navigated a gray zone: men with clear symptoms and low testosterone who do not fit neatly into structural or genetic categories. The April 2026 communication suggests the FDA sees enough maturing evidence—particularly for low libido—to consider a narrower, symptom-anchored indication under idiopathic hypogonadism.

This is not a blanket endorsement of TRT for all symptomatic, low-normal, or age-related cases. Rather, it is a potential path to bring on-label clarity to a subset of men who may benefit when carefully selected, counseled, and monitored.

How Taurus Meds can support patients

  • Education first: We help patients understand the difference between idiopathic and age-related hypogonadism and what the FDA’s evolving position may mean.
  • Thoughtful evaluation: We work with clinicians who follow evidence-based diagnostic pathways and monitoring standards, including blood pressure, hematocrit, and prostate health where appropriate.
  • Ongoing updates: As sponsors engage with the FDA and data requirements come into focus, we will keep our community informed about timelines, results, and any approved label changes.

Our goal is to combine access with safety—ensuring the right patients receive the right therapy with the right oversight.

The bottom line

The FDA’s 2026 announcement on TRT for low libido in idiopathic hypogonadism is a careful, science-led opening—not an approval. It acknowledges maturing evidence, including reassuring MACE results from TRAVERSE alongside important safety signals. If manufacturers deliver strong data, men with well-documented idiopathic hypogonadism and persistent low libido could see clearer on-label treatment options.

Until then, daily practice remains unchanged. Thoughtful evaluation, shared decision-making, and diligent monitoring are essential. For patients, the message is cautiously optimistic: evidence is moving, regulators are listening, and clarity may be coming—if new data confirm that benefits meaningfully outweigh risks in the right patients.

Disclaimer

This article is for informational purposes only and does not constitute medical advice. Do not start, stop, or change any medication without consulting a qualified healthcare professional.

Sources

TRT After Ischemic Stroke in Men With Type 2 Diabetes Safety and Mobility

Posted on by Taurus

TRT After Ischemic Stroke in Men With Type 2 Diabetes: Safety Signals and Mobility Clues From a Small but Notable Study

Estimated reading time: 9 minutes

Key takeaways

  • In a small post-stroke cohort (Morgunov 2018), hypogonadism was prevalent, and TRT with testosterone undecanoate (TU) correlated with mobility and quality-of-life gains over 2–5 years; the nonrandomized design limits causal inference.
  • Contemporary randomized data show no clear increase in nonfatal stroke with TRT over ~2 years, but higher rates of certain non–major adverse events (atrial fibrillation, acute kidney injury, pulmonary embolism) were noted.
  • In 2025, the FDA removed the boxed warning for major cardiovascular events from TRT labeling and added a class-wide warning that TRT can increase blood pressure.
  • In hypogonadal men with T2DM, some trials report improved insulin resistance and metabolic markers with TRT, warranting careful monitoring of blood pressure, hematocrit, and prostate parameters.
  • After ischemic stroke, shared decision-making and structured follow-up across endocrinology, neurology, and cardiology are essential when considering TRT.

Table of contents

  1. Why testosterone matters after stroke—especially with T2DM
  2. What Morgunov 2018 found in hypogonadal men after ischemic stroke
  3. Putting Morgunov into context: What do we know about TRT stroke risk?
  4. 2025 FDA label changes: A clearer, still-cautious safety picture
  5. What about metabolic benefits in T2DM?
  6. Considering TRT after stroke in T2DM: Practical, safety-first themes
  7. Open questions
  8. How Taurus Meds can help
  9. Conclusion
  10. Disclaimer
  11. Sources

Men navigating recovery after an ischemic stroke often discover another challenge hiding in plain sight: low testosterone. For men with type 2 diabetes (T2DM), hypogonadism is even more common—and it may influence how well recovery proceeds. One small observational study suggests testosterone replacement therapy (TRT) with testosterone undecanoate (TU) might support mobility and quality of life after stroke in hypogonadal men. At the same time, larger modern trials and updated FDA labeling remind us to weigh TRT stroke risk and cardiovascular safety signals with care.

This article reviews the Morgunov 2018 cohort, places it in context with broader testosterone–cardiometabolic evidence, and outlines practical considerations for men and clinicians considering TRT after stroke in the setting of T2DM.

Why testosterone matters after stroke—especially with T2DM

Low testosterone is common in men with T2DM and has been linked to reduced lean mass, lower exercise capacity, higher visceral fat, and mood changes. After an ischemic stroke, these factors can compound challenges with rehabilitation, balance, endurance, and motivation. Observational work also suggests that lower testosterone measured during or shortly after an ischemic stroke correlates with worse functional outcomes in the months that follow.

The Morgunov 2018 cohort found hypogonadism in roughly two-thirds of men evaluated after ischemic stroke, with a substantial proportion of hypogonadal cases occurring in men with T2DM. Those findings support what many clinicians see in practice: metabolic disease and neurovascular events often travel together, and androgen deficiency is frequently part of the picture.

What Morgunov 2018 found in hypogonadal men after ischemic stroke

Design at a glance

  • Population: Men recovering from ischemic stroke; 94 were followed.
  • Prevalence: Hypogonadism was identified in ~66% of the cohort overall, with many cases among those with T2DM.
  • Intervention: Injectable testosterone undecanoate (TU) for hypogonadal men; follow-up at 2 and 5 years.
  • Outcomes: Improvements in biochemical (testosterone levels), physical (mobility measures), and mental/quality-of-life parameters were reported in the TRT group.

What this suggests

  • Mobility and independence: TU-based TRT was associated with better mobility and functional markers over time, an outcome that resonates with rehabilitation goals after stroke.
  • Quality of life: Improvements in mood and self-reported well-being were described—potentially important drivers of engagement in rehab and physical activity.
  • Ischemic events: The authors proposed that testosterone deficiency may contribute to ischemic risk and that long-term TRT could support recovery; however, this inference is hypothesis-generating.

Critical limitations

  • Not randomized; no placebo control.
  • Potential selection and survivorship bias.
  • Modest sample size; single-country experience.
  • Not powered to robustly evaluate recurrent stroke or rare adverse events.

Bottom line on Morgunov: It is an intriguing signal—particularly for mobility and quality-of-life outcomes in hypogonadal men with T2DM after stroke—but not definitive evidence. It sets the stage for the key clinical question: can TRT be offered safely to the right post-stroke patient, and under what monitoring framework?

Putting Morgunov into context: What do we know about TRT stroke risk?

Evidence on TRT and cardiovascular events has evolved. Earlier retrospective studies raised concerns about composite risks of mortality, myocardial infarction, and stroke in some populations, while others suggested lower event rates when testosterone was normalized. A 2024 narrative review summarized the conflicting landscape and highlighted that study design, patient selection, and whether testosterone levels were actually restored are crucial variables.

The most consequential update comes from more recent, larger randomized data in men at high cardiovascular risk:

  • Noninferiority for MACE, neutral for stroke: A major cardiovascular-outcomes trial reported that TRT did not increase major adverse cardiovascular events compared to placebo over a median follow-up of about two years, and no signal emerged for increased nonfatal stroke.
  • Non-MACE safety signals: The same program found higher rates of certain non-MACE outcomes—atrial fibrillation (AF), acute kidney injury (AKI), and pulmonary embolism (PE)—in the TRT arm. These findings matter in a post-stroke population, where AF can complicate secondary prevention and PE/VTE risk is already a consideration.

What this means for TRT ischemic safety

  • Stroke specifically: Current high-quality evidence suggests no clear excess in nonfatal stroke with TRT over roughly two years in high-CV-risk men.
  • Broader vascular risk: Caution remains appropriate due to AF, AKI, and PE signals, and because some observational analyses have noted a transient early increase in venous thromboembolism shortly after starting TRT.
  • Individual risk varies: Baseline cardiovascular status, mobility limitations, hydration status, and use of anticoagulation or antiplatelet therapy may modify individual risk.

2025 FDA label changes: A clearer, still-cautious safety picture

In February 2025, the FDA made two notable updates for all testosterone products:

  • Removed: The boxed warning for major adverse cardiovascular events (reflecting noninferiority for MACE in a large outcomes study).
  • Added: A class-wide warning that TRT can raise blood pressure. This stems from ambulatory blood pressure monitoring data, especially with oral testosterone undecanoate formulations approved in recent years.

Practical implications

  • Blood pressure: Even modest, sustained increases in BP can matter after stroke. Clinicians often assess baseline BP carefully and track it during titration and maintenance.
  • Formulation choice: While the BP warning is class-wide, the BP signal was most clearly characterized in the context of oral TU; injectable and transdermal preparations may have different pharmacokinetics and monitoring considerations.

What about metabolic benefits in T2DM?

Several trials in hypogonadal men with T2DM or metabolic syndrome report improved insulin resistance and some favorable shifts in glycemic and lipid parameters with TRT. For example, a 12‑month transdermal study documented reductions in HOMA-IR and improvements in components of metabolic control compared with placebo, without a significant difference in serious adverse events.

How this matters post-stroke:

  • Improved metabolic health may indirectly support rehabilitation by enhancing energy levels, lean mass, and readiness for physical therapy.
  • Not all studies agree, and glycemic responses can differ by baseline status and adherence. Continuous diabetes care and lifestyle measures remain foundational whether or not TRT is used.

Considering TRT after stroke in T2DM: Practical, safety-first themes

  • Confirmation of hypogonadism
    • Diagnosis typically requires both symptoms and consistently low morning testosterone on two separate days.
    • Secondary causes (acute illness effects, certain medications, sleep disorders, pituitary disease) are considered before initiating therapy.
  • Timing relative to stroke
    • Many interventional studies exclude men with a very recent stroke, and timing is individualized. Stabilization of cardiovascular status and blood pressure usually precedes any decision about hormone therapy.
  • Formulation and goals
    • Injectable testosterone undecanoate (as used in Morgunov) offers infrequent dosing and stable levels for many patients. Transdermal formulations provide dose-adjustability and easier reversal if needed.
    • Goals often include symptom relief, functional gains (mobility, endurance), and metabolic support—balanced against cardiovascular, hematologic, and prostate safety.
  • Monitoring and risk mitigation
    • Blood pressure: The class-wide FDA warning makes routine BP tracking central, particularly early after initiation and with dose changes.
    • Hematocrit: TRT can raise red blood cell mass (erythrocytosis), which can thicken blood and potentially elevate thrombotic risk; clinicians generally monitor hematocrit and adjust therapy if it rises too high.
    • Prostate: Baseline PSA and ongoing assessment are common in age-appropriate men, with attention to urinary symptoms and shared decision-making around prostate cancer screening.
    • Cardiometabolic profile: Lipids, glycemic measures, weight, and symptom diaries can help tie treatment decisions to real-world function and quality of life.
    • Rhythm and thromboembolic risk: Given AF and PE signals in large trials, attention to arrhythmia symptoms, mobility plans, hydration, and VTE history is prudent. Coordination with neurology and cardiology can align TRT decisions with secondary stroke prevention.
  • Who may not be a good candidate
    • Men with uncontrolled hypertension, very high hematocrit, active or high-risk prostate cancer, or recent thromboembolic events are often deferred or managed with extreme caution.
    • Fertility plans matter: exogenous testosterone suppresses sperm production and is not a fertility therapy.
  • Setting expectations
    • Benefits, when they occur, are typically gradual. Mobility and quality-of-life gains—like those suggested by Morgunov—are best pursued alongside structured rehabilitation, nutrition, sleep optimization, and diabetes control.

Open questions

  • Can randomized trials in post-stroke hypogonadal men with T2DM confirm the mobility and quality-of-life gains suggested by Morgunov?
  • What is the optimal timing to initiate TRT after ischemic stroke, and what monitoring cadence best balances symptom relief with cardiovascular safety?
  • How do different TRT formulations compare on BP effects, erythrocytosis risk, and adherence in a post-stroke population?
  • How do modern diabetes therapies (e.g., GLP-1 RAs, SGLT2 inhibitors) interact with TRT on mobility, body composition, and vascular outcomes?

How Taurus Meds can help

  • Evidence-grounded counseling on TRT stroke risk and cardiometabolic trade-offs.
  • Coordination across endocrinology, neurology, cardiology, and primary care to align TRT with secondary stroke prevention plans.
  • Practical monitoring pathways for blood pressure, hematocrit, and prostate parameters, tailored to the chosen formulation.
  • Ongoing symptom and function tracking—so therapy remains tied to goals that matter: mobility, energy, and quality of life.

Conclusion

For hypogonadal men with T2DM recovering from ischemic stroke, the Morgunov 2018 cohort offers a cautiously optimistic signal: TRT with TU was associated with improved mobility and quality-of-life measures over years of follow-up. Larger, contemporary trials suggest no clear increase in nonfatal stroke with TRT, although non-MACE signals (AF, AKI, PE) and a class-wide FDA warning about blood pressure underscore the need for careful selection and monitoring.

The path forward is individualized. When hypogonadism is confirmed and symptoms are meaningful, a structured, team-based approach can responsibly test whether TRT helps—anchored in blood pressure vigilance, hematologic and prostate safety checks, and clear functional goals. Until dedicated randomized trials in post-stroke T2DM populations are completed, shared decision-making remains the best compass.

Disclaimer

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about testosterone therapy should be made with a qualified clinician who can assess individual risks and benefits.

Sources

TRT and Atrial Fibrillation Risk What TRAVERSE Means for Monitoring

Posted on by Taurus

TRT and Atrial Fibrillation Risk What TRAVERSE Means for Monitoring

Estimated reading time: ~10 minutes

Key takeaways

  • TRAVERSE found more atrial fibrillation with TRT (3.5%) vs placebo (2.4%) while MACE did not increase; deaths were numerically lower with TRT.
  • The AF signal was a secondary finding with important limitations; a 2025 observational analysis did not confirm a statistically significant AF increase.
  • In February 2025, the FDA removed the boxed MACE warning and added a class-wide blood pressure warning, emphasizing ambulatory BP monitoring (ABPM).
  • Early, individualized monitoring can mitigate non-MACE risks like AF and acute kidney injury (AKI), especially in higher-risk men.
  • Physiologic dosing and avoiding supraphysiologic peaks are linked with better outcomes; VA data associate normalized testosterone with lower AF incidence.

Contents

  1. Introduction
  2. What TRAVERSE actually found
  3. How strong is the AF signal?
  4. What newer data say
  5. The 2025 FDA label update
  6. Practical risk stratification before starting TRT
  7. Monitoring that matches the evidence
  8. The early months: why AF might appear—and how to reduce risk
  9. If you’re already on TRT
  10. Men with prior AF or higher cardiovascular risk
  11. What this means for safety—and for you
  12. Open questions we’re watching
  13. Conclusion

Introduction

Testosterone replacement therapy (TRT) has long carried debate around cardiovascular safety. The 2023 TRAVERSE trial added a new wrinkle: a higher rate of atrial fibrillation (AF) in men assigned to TRT compared with placebo, even as major adverse cardiovascular events (MACE) did not increase. In 2025, the FDA removed the boxed warning for MACE across testosterone products, while adding a class-wide warning about increases in blood pressure—shifting the focus from broad cardiovascular risk to targeted monitoring. Here’s what the latest evidence means if you’re considering TRT, already on therapy, or supporting someone who is.

What TRAVERSE actually found

TRAVERSE was a large, randomized, placebo-controlled trial enrolling 5,246 symptomatic men aged 45–80 with confirmed hypogonadism and preexisting or high cardiovascular risk. Over a median of 33 months:

  • MACE (cardiovascular death, nonfatal MI, nonfatal stroke) was not increased with TRT—the primary safety endpoint was met.
  • TRT recipients experienced more atrial fibrillation: 91 cases (3.5%) vs 63 (2.4%) with placebo (p=0.02).
  • Non-fatal arrhythmias overall were more frequent (p=0.001).
  • AKI occurred more often (60 vs 40 cases; p=0.04).
  • Pulmonary embolism events were numerically higher (0.9% vs 0.5%).
  • Paradoxically, there were 16 fewer deaths in the TRT group, a reassuring if exploratory signal.

This pattern reframes risk: while catastrophic endpoints were not elevated, certain non-MACE events—AF, AKI, and perhaps thromboembolism—merit attention during treatment, especially early on.

How strong is the AF signal?

Important context tempers the AF finding:

  • AF was a secondary outcome without mandated baseline ECGs or protocol-driven rhythm monitoring. Events relied on clinical diagnoses, which can vary in detection and documentation.
  • The study population skewed older with substantial cardiovascular comorbidity—men who already carry higher baseline AF risk.
  • Investigators and commentators have raised the “early mobilization” hypothesis: previously under-active, frail men may abruptly increase activity after TRT initiation (improved energy and anemia correction), transiently unmasking AF before longer-term cardiovascular gains accrue.
  • TRAVERSE did not provide dose-stratified AF analyses, so we cannot link events to supraphysiologic peaks or suboptimal titration.

Bottom line: the AF signal is real in this trial but methodologically limited and may not generalize to younger, lower-risk men or to care settings with tight dose control and proactive monitoring.

What newer data say

Since TRAVERSE, two complementary evidence streams inform interpretation:

  • A 2025 retrospective analysis found an increased risk of AKI with TRT (RR 1.53, 95% CI 1.07–2.18) but did not confirm a statistically significant AF increase (RR 1.48, 95% CI 0.93–2.37). While observational and confounded by design, it suggests AF risk may not be uniform across populations or practice styles.
  • Longitudinal observational data from the Veterans Affairs system indicated AF incidence was lowest in men whose testosterone was normalized to physiologic levels on TRT, compared with men whose levels were not normalized or who remained untreated. This aligns with clinical experience that careful titration and stable physiologic dosing correlate with better rhythm and vascular outcomes.

TRAVERSE also documented correction of anemia in many TRT recipients. Anemia is a recognized cardiovascular risk factor; its improvement could contribute to longer-term benefit that isn’t immediately visible in early safety signals.

The 2025 FDA label update: from broad warnings to targeted monitoring

In February 2025, the FDA removed the boxed warning about MACE from testosterone product labels and added a class-wide warning for increases in blood pressure based on ambulatory blood pressure monitoring data. The shift emphasizes:

  • No demonstrable increase in MACE when TRT is used as indicated in appropriately selected men.
  • Focused vigilance for non-MACE signals—especially blood pressure, arrhythmias, kidney function, and thromboembolic symptoms.
  • The practical value of ABPM and structured follow-up to catch manageable changes before they escalate.

Practical risk stratification before starting TRT

No article can assess your personal risk; that’s the role of your clinician. Still, it helps to understand how many practices approach stratification.

Factors that generally raise baseline AF or complication risk:

  • Prior AF or atrial flutter; known structural heart disease
  • Hypertension, obesity, diabetes, sleep apnea, thyroid disease
  • Chronic kidney disease or borderline renal function
  • Elevated hematocrit at baseline or prior erythrocytosis on TRT
  • Active smoking, heavy alcohol use, stimulant use
  • Age 65+ with multiple cardiovascular comorbidities

Reasonable baseline evaluations to discuss with your care team:

  • Confirmation of biochemical hypogonadism with morning testosterone on two days
  • Cardiovascular review, blood pressure measurement or ABPM
  • Hematocrit/hemoglobin, creatinine/eGFR, electrolytes
  • Consider a baseline ECG if arrhythmia risk is elevated or symptoms suggest palpitations; targeted cardiac evaluation as indicated
  • Sleep apnea screening if snoring, daytime sleepiness, or high STOP-BANG score

At Taurus Meds, we prioritize physiologic dosing and evidence-based monitoring tailored to a patient’s risk profile—particularly in the first few months when most non-MACE signals surface.

Monitoring that matches the evidence

Although schedules vary, the data and FDA update point to a few themes that many clinicians adopt:

  • Blood pressure: Incorporate ABPM or home BP checks, especially during dose titration and after any formulation change.
  • Serum testosterone: Monitor to maintain levels in the mid-normal physiologic range for age; avoid supraphysiologic peaks.
  • Hematocrit: Check periodically; address rising levels promptly to minimize thrombotic risk.
  • Renal function: Reassess creatinine/eGFR after initiation and with dose changes, particularly in men with preexisting kidney risk.
  • Symptoms review: Ask about palpitations, rapid or irregular heartbeat, dizziness, chest discomfort, decreased urine output, leg swelling, or sudden shortness of breath.

Cleveland Clinic authors have noted that outcomes depend on indication-based prescribing and vigilant monitoring to avoid excessive dosing—something that may not be consistently practiced in all settings. If care is fragmented, advocate for a clear follow-up plan.

The early months: why AF might appear—and how to reduce risk

If AF events cluster early, several modifiable factors may help reduce risk:

  • Gradual activity ramp-up: Rising energy is a common early benefit; a measured increase in physical activity may be safer than an abrupt jump from sedentary to vigorous exercise in men with underlying heart disease.
  • Dose and formulation: Avoid supraphysiologic peaks. Discuss whether your formulation’s pharmacokinetics align with stable levels for you.
  • Blood pressure and volume status: Monitor BP closely; manage salt intake prudently; maintain hydration, particularly with exercise or heat exposure.
  • Sleep and alcohol: Treat sleep apnea when present; moderate alcohol and avoid binge drinking, which can precipitate AF.
  • Interacting substances: Review decongestants, stimulants, and supplements with your clinician.

These are not substitutes for medical care but practical levers that, combined with individualized follow-up, may blunt early arrhythmia risk.

If you’re already on TRT

  • Do not stop therapy abruptly without talking to your prescriber. Sudden changes can cause symptom rebound and complicate evaluation.
  • Report new palpitations, irregular heartbeat, chest discomfort, shortness of breath, lightheadedness, decreased urination, or leg swelling promptly.
  • Keep lab and monitoring appointments. Dose adjustment to maintain physiologic levels is a safety feature, not merely a “check-the-box” task.
  • Share any ER or urgent care visits with your TRT clinician so findings (e.g., ECGs) inform your ongoing plan.

Men with prior AF or higher cardiovascular risk

TRAVERSE included men at elevated cardiovascular risk, and still showed no increase in MACE. However, for those with established AF, heart failure, advanced kidney disease, or multiple risk factors, conversations typically include:

  • Cardiology co-management, especially if AF has been symptomatic or difficult to control
  • Baseline ECG and, when indicated, rhythm monitoring
  • Early and more frequent follow-up during the first 3–6 months
  • Clear thresholds for contacting the care team if symptoms arise

TRT may still be appropriate in select patients when hypogonadism is confirmed and benefits justify risks; this is a nuanced, shared decision-making process.

What this means for safety—and for you

The weight of evidence now supports a refined message:

  • When TRT is prescribed for true hypogonadism and carefully titrated, MACE does not appear elevated, which the FDA recognized by removing the boxed warning.
  • Non-MACE safety signals—including AF, AKI, and potential thromboembolism—are real but manageable with patient selection, physiologic dosing, and proactive surveillance.
  • Long-term, steady, physiologic testosterone levels may even relate to lower AF incidence in real-world cohorts, underscoring the value of dose control and adherence.

For men exploring TRT, the practical question is less “Is TRT categorically safe or unsafe?” and more “What is my individual risk, and how will my care team monitor and mitigate it—especially early on?”

At Taurus Meds, we approach TRT as a longitudinal partnership: confirm the diagnosis, personalize dosing to physiologic targets, use ABPM and lab monitoring where it adds value, and keep communication open if symptoms evolve.

Open questions we’re watching

  • Mechanism: Why did TRAVERSE show more AF while normalized testosterone in observational data corresponded to less AF? Is early unmasking the key, or is there a biological threshold effect?
  • Early vs. long-term risk: What intensity and duration of early monitoring best minimize AF and AKI without overburdening patients?
  • Dose-response: Which serum levels or pharmacokinetic patterns best separate benefit from risk in diverse populations?
  • Real-world practice: How often are indication-based prescribing and titration achieved outside of clinical trials?
  • Subgroups: Which baseline characteristics most strongly predict secondary safety signals, and can we tailor follow-up accordingly?
  • AKI and PE: What are the dominant mechanisms, and how reversible are these events with dose adjustment or discontinuation?

Conclusion

TRAVERSE reshaped the conversation: MACE risk is not the main barrier to TRT for appropriately selected men, but non-MACE events—especially AF and AKI—deserve targeted, early vigilance. The 2025 FDA label update aligns with this nuance, emphasizing blood pressure monitoring and individualized follow-up rather than blanket warnings.

For patients and clinicians, the path forward is practical: confirm true hypogonadism, stratify risk thoughtfully, titrate to physiologic levels, and monitor early and consistently. Done this way, TRT can be both effective and responsibly managed—minimizing transient risks while pursuing durable benefits.

Disclaimer

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional about your specific health questions and before making changes to your medications or treatment plan.

Sources

Ex Vivo TU Conversion and Oral TRT Dosing Accuracy

Posted on by Taurus

Ex Vivo TU Conversion and Oral TRT Dosing Accuracy

Ex vivo conversion of TU to testosterone can inflate lab values after a blood draw, risking dosing errors. With 3–6 hour timing and validated plain tubes, clinics can monitor oral TRT accurately without special supplies.

Estimated reading time: 10 minutes

Key takeaways

  • Ex vivo conversion of testosterone undecanoate (TU) to testosterone (T) after the blood draw can inflate measured T and mislead dosing decisions if not controlled.
  • FDA concerns were resolved with tube/processing validation, PK modeling, and a small adjustment factor enabling accurate monitoring without special collection supplies.
  • A single 3–6 hour post-dose sample (commonly 4–6 hours) using validated plain tubes reliably reflects average exposure for Jatenzo and Tlando titration.
  • NaF/EDTA tubes suppress ex vivo conversion but may under-report T at higher TU levels; labels rely on validated plain-tube methods instead.

Table of contents

  1. Why Oral TRT Monitoring Got Complicated
  2. What the FDA Required—and How It Was Resolved
  3. What the Studies Actually Found
  4. Practical Implications for Oral TRT Monitoring
  5. Safety Context: What Else Gets Monitored
  6. Limitations and Open Questions
  7. Considerations for Clinics and Laboratories
  8. What This Means for Patients on Jatenzo or Tlando
  9. How Taurus Meds Approaches Oral TRT Monitoring
  10. Conclusion
  11. Disclaimer
  12. Sources

Why Oral TRT Monitoring Got Complicated

Oral testosterone undecanoate (TU) products like Jatenzo and Tlando have made testosterone replacement therapy (TRT) more convenient for many men. But they also introduced a technical challenge for labs and clinicians: blood draws can overestimate testosterone if TU in the sample converts to testosterone (T) after the draw. The FDA scrutinized this issue for years. The good news: tube and processing validation now support reliable oral TRT monitoring using a single timed blood draw—without exotic collection supplies—when conducted according to product labeling and validated methods.

This section explains what changed, why it matters for accuracy, and what patients and clinics should understand about timing, tube type, and interpretation.

  • Mechanism: Plasma and serum contain esterases that can cleave TU into T after collection. If this happens in the tube, the assay “sees” more T than was in circulation at draw time.
  • Clinical consequence: Overestimation of serum T can prompt down-titration or maintenance of a subtherapeutic dose.
  • Concentration dependence: Ex vivo conversion is more pronounced when post-dose TU is higher, making timed draws sensitive to handling.

What the FDA Required—and How It Was Resolved

Tlando’s multi-year review history illustrates the issue and its resolution. Between 2016 and 2019, the FDA issued Complete Response letters for Tlando, citing an inability to exclude clinically relevant ex vivo conversion as a source of bias in measured testosterone. This was not about efficacy; it was about ensuring routine lab methods could guide dosing accurately.

Two strands of evidence resolved the concern:

  1. Tube and processing validation

    • Ex vivo TU-to-T conversion is concentration-dependent.
    • NaF (±EDTA) tubes reduced conversion by roughly 30–85% versus plain tubes.
    • At higher TU levels (e.g., >15 ng/mL), NaF tubes produced ~14–30% lower measured T, suggesting under-reporting at clinically relevant concentrations.
    • Cold processing (~4°C) minimized ex vivo conversion across tube types.
  2. PK modeling, simulations, and a small adjustment factor

    • For Jatenzo and Tlando, modeling linked a single timed post-dose T value to 24-hour average exposure (Cavg), the efficacy anchor.
    • The strongest window was 3–6 hours post-dose (often ~4 hours), with ~88–95% concordance with Cavg.
    • A small validated correction (about 3% in some analyses; up to ~3–8% for parameters like Cmax) aligned plain-tube measurements with true exposure.

This evidence enabled Jatenzo’s approval (2019) and Tlando’s subsequent approvals. Plain tubes with validated timing/processing—and a small adjustment—met the FDA’s practicality and accuracy bar.

What the Studies Actually Found

  • Ex vivo conversion is real but manageable. Cooling and timely separation mitigate the effect, which is larger when TU is high.
  • NaF/EDTA tubes reduce conversion but may under-report T when TU concentrations are higher, complicating universal use.
  • Modeling supports a single timed sample. A 3–6 hour post-dose draw correlates well with Cavg for eugonadal targeting.
  • High concordance with Cavg. Analyses for Jatenzo and Tlando reported ~88–95% agreement using the validated timing and plain-tube approach.
  • Phase 3 outcomes aligned. Tlando’s fixed-dose regimen and Jatenzo’s titratable regimen met efficacy targets using these methods.

Caution: Inter-site variability may occur; a site with irregular handling produced outlier Cmax values in one FDA review—underscoring the importance of consistent timing and processing.

Practical Implications for Oral TRT Monitoring

  • A single, timed post-dose sample works. Labels rely on a 3–6 hour post-dose draw (commonly 4–6 hours) to gauge average exposure.
  • Plain tubes are acceptable when used as validated. No exotic tubes are required in routine practice when handling follows validated methods.
  • Why not always use NaF/EDTA? They lessen conversion but can under-report T at higher TU levels; labeling reflects a practical, validated plain-tube approach with a small correction.
  • Timing matters. Drawing too early or too late can misrepresent exposure; the 3–6 hour window is PK-driven.
  • Interpretation guides titration. Clinicians use the timed T value to adjust within approved ranges, aiming for eugonadal exposure while monitoring safety labs.

Safety Context: What Else Gets Monitored

  • Blood pressure: Oral TU products carry a boxed warning for BP increases (often ~3–5 mmHg). Baseline CV risk assessment and on-therapy monitoring are standard.
  • Hematologic changes: Average hematocrit increases (e.g., ~3.2%) occur with TRT. Baseline and periodic checks are recommended.
  • Contraindications and precautions: As with all TRT, observe label-directed warnings (e.g., prostate/breast cancer considerations) and routine safety monitoring.

Limitations and Open Questions

  • Universal adjustment factor: The exact correction may vary across doses, populations, and lab platforms.
  • Real-world performance: Community variability in timing, handling, and assays can influence accuracy.
  • High TU concentrations: The NaF vs. plain-tube differences at very high TU levels warrant ongoing attention.
  • Populations studied: Precision data often come from Phase 1/3 hypogonadal male cohorts; broader generalizability is inferred.

Considerations for Clinics and Laboratories

  • Align the draw with dosing: Schedule testosterone measurement 3–6 hours post-dose per product labeling.
  • Use validated plain tubes: These underpinned efficacy/safety decisions and are practical with proper handling.
  • Emphasize prompt, controlled processing: Cooling and timely separation reduce ex vivo conversion variability.
  • Be alert to outliers: Unexpected values, or deviations in timing/handling, may merit repeat testing.

Consistency in timing and handling—more than tube type alone—drives reliable results.

What This Means for Patients on Jatenzo or Tlando

  • Expect a timed blood draw: Typically a few hours after your dose (not before dosing), unlike some injection/gel protocols.
  • Standard labs are usually fine: Routine supplies and validated plain tubes are typically sufficient.
  • Share details with your lab: Confirm product name and timing so staff coordinate the post-dose window correctly.
  • Stay current on safety labs: Blood pressure checks and periodic hematologic labs remain part of care.

How Taurus Meds Approaches Oral TRT Monitoring

  • We coordinate with labs that understand the 3–6 hour post-dose timing used in labeling.
  • We interpret results alongside symptoms, safety parameters, and consistent lab methods.
  • We titrate within approved strategies to maintain eugonadal exposure while prioritizing safety and practicality.

Our goal: predictable, reproducible monitoring—so dose decisions reflect physiology, not collection artifacts.

Conclusion

Ex vivo conversion of TU to testosterone in blood samples was a legitimate hurdle for oral TRT monitoring. Through multiple FDA review cycles, manufacturers demonstrated that a single, timed post-dose sample collected in plain tubes—paired with validated handling and a small adjustment—accurately reflects average testosterone exposure for Jatenzo and Tlando. This enables practical, clinic-friendly monitoring without sacrificing reliability.

Open questions persist around universal adjustments and real-world workflow variability, but the core message is encouraging: with attention to timing and consistent processing, oral TRT can be monitored accurately enough to guide dosing decisions, while maintaining regular safety surveillance for blood pressure and hematologic effects.

Disclaimer

This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalized recommendations on TRT monitoring and dosing.

Sources

TRT for Men in Their 40s Benefits, Outcomes, and Mid-Term Safety

Posted on by Taurus

TRT for Men in Their 40s Benefits, Outcomes, and Mid-Term Safety

Estimated reading time: 8 minutes

Key takeaways

  • In appropriately selected men 40–49 with confirmed hypogonadism, TRT can improve sexual function, increase lean mass, reduce fat mass, and favorably shift metabolic markers.
  • Mid-term safety (~12–36 months) is generally reassuring for major adverse cardiovascular events, though signals like atrial fibrillation, acute kidney injury, and pulmonary embolism warrant monitoring.
  • Key risks include erythrocytosis (more common with injections), prostate-related findings requiring surveillance, and suppression of fertility while on therapy.
  • Evidence specific to men in their 40s is growing but still leans on broader-age studies; long-term outcomes beyond 5–10 years remain uncertain.
  • TRT is not for “healthy aging” or performance enhancement; diagnosis should pair compatible symptoms with two low early-morning testosterone levels.

Table of contents

  1. Why low T shows up in the 40s
  2. What the 2025 review found for 40–49 year olds
  3. Safety: What mid-term data say
  4. Who may benefit—and who should pause
  5. Practical expectations and timeline
  6. Formulations, delivery, and monitoring nuances
  7. The regulatory landscape in 2025
  8. Open questions for this decade
  9. How Taurus Meds supports informed, cautious care
  10. Conclusion

Why low T shows up in the 40s

Many men in their 40s notice lower libido, softer muscle tone, more central fat, lower energy, and mood changes. For some, these reflect confirmed hypogonadism rather than “normal aging.” Total testosterone declines gradually with age, but not universally. In the 40–49 bracket, about 6–12% of men have low testosterone, often influenced by metabolic factors like obesity, insulin resistance, type 2 diabetes, and obstructive sleep apnea.

Diagnosis matters. Guidelines and trials define clinically significant hypogonadism as compatible symptoms plus two separate early‑morning total testosterone measurements below 300 ng/dL. Without both, benefits are less likely and risks may outweigh gains.

What the 2025 review found for 40–49 year olds

A 2025 narrative review synthesizing age-specific data for men 40–49 summarized consistent benefits across randomized trials and meta-analyses when hypogonadism is clearly established:

  • Sexual function: Improved libido and erectile function were common, especially with baseline testosterone below 300 ng/dL and prominent sexual symptoms.
  • Body composition: Lean mass tended to rise while fat mass declined, with the best results when TRT was paired with nutrition, resistance training, and weight management.
  • Metabolic outcomes: Improvements in insulin sensitivity and reductions in waist circumference were observed; these are additive to lifestyle and, when needed, medications.
  • Bone, mood, vitality: Androgen repletion supports bone health over time; many men report better energy and vitality. Mood improvements are variable and context-dependent.

Bottom line: For properly selected men in their 40s, benefits are real and reproducible, though effect sizes vary.

Safety: What mid-term data say

Mid-term safety is a central question for men early in midlife. Findings from the large randomized, placebo-controlled TRAVERSE program (5,246 men aged 45–80; median follow-up ~33 months) are instructive, including secondary analyses of non-MACE outcomes:

  • MACE: No significant increase in major adverse cardiovascular events versus placebo in the overall population.
  • Non-MACE signals: Numerical increases in atrial fibrillation, acute kidney injury, and pulmonary embolism were observed, warranting judicious selection and routine monitoring.
  • Quality of life: Sexual function and broader QoL improvements were consistent with prior research.

Other key safety considerations:

  • Erythrocytosis: Most common lab issue; more frequent with intramuscular injections than topicals. Manage with dose/formulation adjustments or phlebotomy, guided by routine labs.
  • Prostate: Mid-term data do not show increased prostate cancer risk, but PSA can rise and may unmask pathology; baseline assessment and surveillance are standard.
  • Fertility: Exogenous testosterone suppresses spermatogenesis; men planning children should consider alternatives (e.g., SERMs, gonadotropins).
  • Sleep apnea and fluid: Untreated sleep apnea can worsen; some men experience edema.

For men specifically in their 40s, the mid-term picture is reassuring but not definitive; long-term (>5–10 years) cardiovascular and prostate outcomes need more age-specific data.

Who may benefit—and who should pause

You may be a candidate to discuss TRT if:

  • You have consistent symptoms (e.g., reduced libido, erectile difficulties, decreased morning erections, fatigue, loss of muscle/strength, increased abdominal fat, low mood), and
  • Two separate early‑morning total testosterone levels are below 300 ng/dL under stable health conditions, and
  • Other causes of symptoms (thyroid disease, depression, medication effects, heavy alcohol use, untreated sleep apnea) have been considered.

You may need to pause or think differently if:

  • You are trying to conceive soon.
  • You have uncontrolled cardiovascular disease or a recent major cardiovascular event.
  • You have untreated severe sleep apnea, very high hematocrit, or concerning prostate findings pending evaluation.
  • Your testosterone is borderline/normal and symptoms point elsewhere.

Best outcomes often come from integrated care: endocrine evaluation, cardiometabolic risk reduction, sleep and mental health review, and individualized monitoring.

Practical expectations and timeline

  • Weeks 2–6: Libido may begin improving; some men note better energy, motivation, and sleep.
  • Weeks 6–12: Ongoing gains in erectile function and sexual satisfaction; training capacity and recovery often feel better.
  • Months 3–6: Measurable body composition changes (↑ lean mass, ↓ fat mass), especially with resistance training and nutrition support.
  • Months 6–12+: Continued favorable trends in insulin sensitivity and waist circumference, particularly alongside lifestyle changes.

Expect periodic labs (e.g., hematocrit, PSA) and symptom reviews; dose and formulation adjustments are common to balance benefit and side effects.

Formulations, delivery, and monitoring nuances

  • Topical gels/solutions: Steady levels; daily use; transference risk; generally lower erythrocytosis risk.
  • Intramuscular/subcutaneous injections: Flexible dosing; higher peaks/troughs without careful titration; higher erythrocytosis risk.
  • Other options: Routes and convenience vary as new formulations evolve.

Monitoring themes for men in their 40s:

  • Hematocrit trends and thresholds linked to clotting risk.
  • PSA and prostate symptoms, with urology input as indicated.
  • Cardiometabolic profile: blood pressure, lipids, glucose/insulin sensitivity, weight, and waist circumference.
  • Symptom tracking: sexual function, energy, mood, sleep, and exercise capacity.

The regulatory landscape in 2025

As of late 2025, the FDA continues to center TRT indications on classical hypogonadism, while noting it will consider supplemental applications for idiopathic hypogonadism with specific symptom targets such as low libido. See the agency’s update: FDA announcement on testosterone therapy considerations.

In practice: Clear documentation of symptoms with corroborating low testosterone remains essential; off-label use should be guided by emerging evidence, safety monitoring, and individualized risk–benefit discussions.

Open questions for this decade

  • Long-term safety: More age-specific data beyond 5–10 years for cardiovascular and prostate outcomes are needed.
  • Precision medicine: Can genetics, SHBG, or body composition predict response and risk?
  • Formulation/dosing: Better head-to-head trials to optimize benefit while minimizing erythrocytosis and other adverse events.
  • Metabolic strategy: How TRT compares or combines with GLP‑1 receptor agonists and other weight-centric therapies in men with obesity/metabolic syndrome.
  • Fertility-preserving pathways: Optimal protocols for symptom relief while maintaining or restoring spermatogenesis.

How Taurus Meds supports informed, cautious care

Taurus Meds emphasizes individualized, evidence-based evaluation for men in their 40s considering TRT. We focus on careful symptom assessment, biochemical confirmation, and discussions about goals, risks, fertility, and alternatives. When TRT is appropriate, we integrate monitoring, lifestyle optimization, and dose/formulation choices tailored to your health profile. When it isn’t, we help you pursue other paths to better energy, sexual health, and body composition.

Conclusion

For men in their 40s with confirmed hypogonadism, TRT can meaningfully improve sexual function, lean mass, fat distribution, and metabolic markers—especially when paired with sleep optimization, resistance training, nutrition, and weight management. Mid-term safety data are reassuring regarding major cardiovascular events, but non-MACE signals and known risks like erythrocytosis, prostate considerations, and fertility suppression require careful monitoring. The strongest results occur when diagnostic criteria are met, targets are clear, and clinicians track outcomes and adjust along the way.

Disclaimer

This article is for informational purposes only and does not constitute medical advice. It does not replace professional evaluation, diagnosis, or treatment. Always consult a qualified healthcare professional about your specific situation.

Sources

TRT and Acute Kidney Injury What Recent Safety Reviews Show

Posted on by Taurus

TRT and Acute Kidney Injury What Recent Safety Reviews Show

Estimated reading time: ~10 minutes

Key takeaways

  • A modest AKI signal has emerged in higher-risk men on TRT, with low absolute rates (roughly a 1–2% absolute difference over several years).
  • TRAVERSE and real-world cohorts show elevated AKI risk, while other observational work is neutral—underscoring uncertainty and the value of monitoring.
  • Early therapy (3–6 months), obesity, diabetes, and hypertension appear to mark higher risk; blood pressure and hematocrit are key safety levers.
  • No hydration “threshold” prevents AKI, but steady hydration and avoidance of dehydration during illness, heat, or intense training are prudent.
  • Shared decision-making and a structured safety plan help preserve TRT benefits while managing kidney risk.

Table of contents

  1. Overview: Acute kidney injury signals in TRT users
  2. What the latest evidence shows
  3. How might TRT influence kidney risk?
  4. Who may need closer monitoring?
  5. Practical monitoring for renal safety on TRT
  6. Hydration and lifestyle considerations
  7. Oral vs injectable TRT: Any difference for the kidneys?
  8. What we still don’t know
  9. How Taurus Meds approaches renal safety
  10. Conclusion

Overview: Acute kidney injury signals in TRT users

Testosterone replacement therapy (TRT) is increasingly prescribed for symptomatic hypogonadism, and its cardiovascular safety has been studied intensively. Less discussed—but important for men weighing risks and benefits—is kidney safety. Recent evidence, including secondary outcomes from the TRAVERSE randomized trial and newer real-world analyses, suggests a small increase in acute kidney injury (AKI) among certain TRT users. This article unpacks what that signal means, who it might affect most, and how practical monitoring and hydration habits can support safer therapy.

What the latest evidence shows

Two types of studies inform the current view of TRT kidney injury risk: randomized trial data and observational real-world cohorts.

  • TRAVERSE randomized controlled trial: In men with hypogonadism and high cardiovascular risk, AKI occurred in 2.3% of those assigned to TRT vs 1.5% with placebo (P=0.04). Although AKI was a secondary outcome and the trial was not powered specifically for renal endpoints, the difference was statistically significant and prompted attention to renal safety alongside other non-MACE signals (like atrial fibrillation and pulmonary embolism).
  • Real-world cohort data (Journal of Sexual Medicine, 2025–2026): A multi-year analysis of 4,268 hypogonadal men found AKI in 3.5% of TRT users vs 2.3% of non-users over approximately three years (P=0.018; relative risk 1.53, 95% CI 1.07–2.18). TRT users in this study had more cardiometabolic comorbidity at baseline (e.g., higher rates of obesity and diabetes), which could partly explain the difference but does not fully negate the signal.

Context matters. Absolute AKI rates remained low in both studies, and the observed risk increase translates to a modest absolute difference (around 1–2% over several years in higher-risk men). Notably, some broader observational studies (outside high-risk cohorts) report neutral or slightly lower AKI risk with TRT, highlighting how baseline risk, selection criteria, and confounding can alter findings. Taken together, the data suggest TRT kidney injury risk is small but real in certain populations and warrants routine kidney- and blood-pressure–focused monitoring.

How might TRT influence kidney risk?

Potential contributors to AKI risk on TRT include:

  • Blood pressure effects: Ambulatory blood pressure monitoring in clinical reviews of oral testosterone undecanoate formulations demonstrated average increases in blood pressure. Even small sustained BP rises can increase renal workload, particularly in men with pre-existing hypertension or CKD risk.
  • Erythrocytosis and viscosity: TRT can raise hematocrit. Higher blood viscosity may, in theory, reduce renal microcirculatory reserve during dehydration or acute illness. Hematocrit above 54% is a recognized threshold to pause or adjust therapy.
  • Volume status: Dehydration from illness, heat exposure, or intense training—especially when combined with diuretics or NSAIDs—can precipitate AKI. If TRT also nudges blood pressure or hematocrit upward, this may further narrow the margin for error.
  • Underlying comorbidity: Obesity, diabetes, and hypertension are common in men seeking TRT and independently increase AKI risk. The real-world study found higher rates of these conditions among TRT users, which may amplify vulnerability.
  • Mechanisms still uncertain: There is no consensus on a direct nephrotoxic effect of testosterone at physiologic replacement doses. The signal could reflect hemodynamic changes, susceptibility in at-risk men, or residual confounding in observational designs.

Who may need closer monitoring?

Based on the trials, regulatory reviews, and real-world patterns, closer renal safety monitoring is especially relevant for:

  • Men with obesity (BMI ≥30), diabetes, or hypertension
  • Those with borderline renal function at baseline or a history of AKI
  • Early in therapy (first 3–6 months), when many physiologic adjustments occur
  • Users of medications that influence renal perfusion (e.g., ACE inhibitors/ARBs, diuretics) or nephrotoxic agents (e.g., frequent NSAID use), particularly during illness or dehydration
  • Men on formulations associated with blood pressure increases or men who have rising hematocrit on therapy

None of these factors automatically disqualify someone from TRT, but they raise the value of baseline assessment and scheduled follow-up.

Practical monitoring for renal safety on TRT

While protocols vary, a cautious, patient-centered monitoring approach can help detect issues before they become problems.

  • Before starting:
    • Confirm hypogonadism with appropriate testing and review comorbidities.
    • Baseline labs: serum creatinine and eGFR; hematocrit/hemoglobin; blood pressure assessment. Consider urinalysis if CKD risk is present.
  • Early follow-up:
    • Recheck renal function and blood pressure at approximately 3–6 months after initiation or dose adjustment.
    • Monitor hematocrit; many programs pause or modify therapy if hematocrit exceeds 54%.
  • Ongoing surveillance:
    • Annual kidney function and hematologic monitoring for lower-risk men; more frequent checks if CKD, diabetes, hypertension, or rising hematocrit is present.
    • Encourage home blood pressure tracking, especially for those on oral testosterone undecanoate or with borderline office readings.
  • Red flags prompting clinician contact:
    • A sustained, unexplained rise in creatinine or drop in eGFR compared with baseline
    • New or worsening hypertension, headaches, or edema
    • Symptoms of possible AKI (e.g., reduced urine output, flank pain, severe fatigue), especially during or after acute illness, dehydration, or use of nephrotoxic medications

These steps are not a substitute for individualized medical care; they reflect the themes emphasized in trial findings and regulatory reviews focused on BP and hematologic effects.

Hydration and lifestyle considerations

No trial has established that hydration “prevents” TRT kidney injury, and no evidence-based intake threshold has been defined. Still, basic hydration and recovery habits matter for kidney health, especially in men with comorbidities.

  • Aim for consistent day-to-day hydration; adjust upward during heat, heavy training, fever, or gastrointestinal illness.
  • Discuss sick-day plans with your clinician if you take medications that can affect kidney blood flow (e.g., diuretics, ACE inhibitors/ARBs). Avoiding dehydration plus high-dose NSAIDs during illness is often prudent.
  • Moderate alcohol; minimize unnecessary NSAID use.
  • Support blood pressure control through nutrition, sleep, and activity. Weight reduction in men with obesity can benefit BP, glycemic control, and renal workload—and may improve TRT response.
  • Keep dosing steady and avoid supraphysiologic peaks. Staying within therapeutic ranges helps limit hematocrit rise and blood pressure shifts.

Again, these are general kidney-friendly practices. They complement, but do not replace, lab monitoring and clinician oversight.

Oral vs injectable TRT: Any difference for the kidneys?

Large head-to-head renal safety comparisons between injectable and oral formulations are limited. However:

  • Regulatory reviews for oral testosterone undecanoate approvals emphasized blood pressure increases on ambulatory monitoring and rises in hematocrit. Neither review highlighted a specific AKI signal in phase 3 programs.
  • Because blood pressure and hematocrit can influence renal risk, men on any formulation should have these parameters tracked. For oral TU, BP monitoring deserves special attention given the observed average increases.
  • In the real-world AKI analysis, formulation-specific kidney outcomes were not the primary focus. The overall pattern suggests patient factors (obesity, diabetes, hypertension) may carry as much or more weight than formulation choice.

Bottom line: choose a formulation with your clinician that achieves physiologic replacement and is practical for adherence and monitoring, then follow a structured safety plan.

What we still don’t know

  • Causality and mechanisms: Is the AKI signal driven by BP changes, hematocrit-related viscosity, unmeasured confounding, or a direct renal effect?
  • Timing: Are the first 3–6 months the highest-risk window, and does risk plateau thereafter?
  • Long-term outcomes: How does AKI risk evolve beyond three years, and does TRT influence chronic kidney disease progression differently across risk groups?
  • Prevention strategies: Can tailored hydration, careful NSAID use, and BP optimization measurably reduce AKI risk on TRT, and by how much?
  • Best monitoring cadence: What follow-up schedule maximizes safety while minimizing burden in varied risk profiles?

How Taurus Meds approaches renal safety

  • We start with a thorough baseline evaluation, including renal function, hematocrit, and blood pressure.
  • Early follow-up at 3–6 months helps catch trends in eGFR, creatinine, BP, and hematocrit.
  • We individualize surveillance intensity for men with obesity, diabetes, hypertension, or early CKD.
  • Patients receive practical guidance on hydration, sick-day considerations, and when to contact the care team.
  • We coordinate with primary care and cardiometabolic specialists when needed to align goals and reduce polypharmacy risks.

This approach aims to preserve the benefits of TRT while managing the small but meaningful risk of kidney injury.

Conclusion

The best current evidence suggests a modest increase in AKI among higher-risk men on TRT, with low absolute event rates. TRAVERSE and real-world data align in signaling an elevated risk, while other observational work indicates the story may be more nuanced in broader populations. Until more definitive answers arrive, practical steps—baseline assessment, early and periodic monitoring of renal function, blood pressure, and hematocrit, plus attention to hydration and comorbidities—offer a balanced path forward.

For men considering TRT or already on therapy, the question is not “Is TRT safe for kidneys?” but rather “What is my personal kidney risk, and how will we monitor and manage it?” With structured oversight and shared decision-making, most men can navigate TRT kidney injury concerns thoughtfully and safely.

Disclaimer

This article is for educational purposes only and is not a substitute for personalized medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional about your specific health circumstances.

Sources